Management of chronic hepatitis B in childhood: ESPGHAN clinical practice guidelines

Presented by


More than 360 million persons worldwide (6% of the world population) are chronically infected by the hepatitis B virus (HBV). Although the incidence of HBV infection has dramatically declined since the implementation of universal immunization programs in several countries and blood-donor screening, a significant number of children are still infected each year, often developing chronic infection and requiring appropriate follow-up. Despite a rather benign course of chronic hepatitis B (CHB) during childhood and adolescence, 3–5% and 0.01–0.03% of chronic carriers develop cirrhosis or hepatocellular carcinoma (HCC), respectively, before adulthood.

Keywords: hepatitis B virus; chronic hepatitis B; treatment; children; adolescents; management; resistance; breastfeeding; immunosuppressed; transplantation; acute hepatitis B; pregnancy; tenofovir disoproxil fumarate; term follow-up; E-antigen seroconversion; spontaneous HBeAg seroconversion; sustained virological response; interferon-alpha treatment; placebo-controlled trial; virus-infected patients; HBsAg-carrier children; acute liver failure

Available Languages


Source File

Publishing organization(s):

ESPGHAN European Society for Paediatric Gastroenterology, Hepatology and Nutrition

Scientific area:

Hepatobiliary, Paediatrics

This item can be cited as:  Journal of Hepatology 2013 vol. 59 j 814–829; PMID 23707367


  • Format
    • Standards and Guidelines
  • Language
    • English
  • UEG Member Society
    • European Society for Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN)
  • UEG Week Pathway
    • Hepatobiliary
    • Paediatrics
  • Year
    • 2013